COLINZ LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 7 | 7 | 7 | 7 | 6 |
| EBITDA (ex other income) | 1 | 1 | 1 | 0 | 0 |
| margin % | 8.4 | 8.5 | 7.7 | 7.6 | 6.6 |
| Owners' profit | 0 | 0 | 0 | 0 | 1 |
| EPS, as reported (₹) | 0.74 | 1.82 | 1.93 | 1.97 | 2.04 |
| ROE % · ROCE % | 4.4 · 7.0 | 5.6 · 7.8 | 5.4 · 7.5 | 5.2 · 6.9 | 5.1 · 7.3 |
| Debt / equity (x) | 0.06 | 0.03 | 0.06 | 0.07 | 0.04 |
| Cash from operations | 0 | 0 | 1 | (1) | 3 |
| Capex | (0) | 0 | 0 | (0) | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| EPS (₹) | 0.62 | 0.00 | 0.60 | 0.54 | 0.56 | 0.33 | 0.68 | 9.53 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Colinz Laboratories open offer closes with only 6 shares tendered | strategic transactions | medium | — | — |
| 27 Aug 2026 · 40th AGM notice published; book closure 15-22 Sep 2026 | compliance | minimal | — | — |
| 20 Aug 2026 · Colinz Laboratories files 40th Annual Report for FY 2025-26 | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Book Closure from 15 to 22 Sep 2026 for 40th AGM | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Notice of 40th AGM on 22 Sept 2026 via video conferencing | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Open Offer for 26% stake in Colinz Laboratories at Rs 54 per share | strategic transactions | high | — | — |
| 5 Aug 2026 · Open Offer at Rs 54 per share for Colinz Labs - IDC recommendation published | compliance | minimal | — | — |
| 31 Jul 2026 · Open Offer at Rs 54 per share to acquire 26 percent stake in Colinz Laboratories | strategic transactions | high | — | — |
| 31 Jul 2026 · Colinz Labs Q1 PAT jumps to Rs 240 lacs on asset sale proceeds | compliance | minimal | — | — |
| 30 Jul 2026 · Colinz Labs Q1 FY26-27: PAT jumps to 240L on one-time asset sale; revenue dips 21% | results | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| CIPLA LTD |
| 1,10,352 |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 6.5 | 28.9 | 13 of 169 | 93% |
| P/B | 1.8 | 3.3 | 46 of 163 | 72% |
| ROCE | 6.9 | 10.8 | 117 of 183 | 36% |
| ROE | 5.1 | 10.4 | 121 of 171 | 29% |
| Debt / Equity | 0.0 | 0.1 | 64 of 171 | 63% |
| EBITDA margin | 237.5 | 17.5 | 1 of 165 | 100% |
| Revenue growth | (20.8) | 16.3 | 141 of 161 | 13% |
| Profit growth | 1914.4 | 30.9 | 5 of 158 | 98% |
| Market cap | 18 | 839 | 166 of 182 | 9% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
